Literature DB >> 23247772

A proposal for a simplified MASCC score.

Jasmijn C A Wierema, Matthew Links.   

Abstract

Mesh：

Year:  2012        PMID： 23247772     DOI： 10.1007/s00520-012-1676-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  18 in total

1.  Management of febrile neutropenia: ESMO Clinical Practice Guidelines.

Authors:  J de Naurois; I Novitzky-Basso; M J Gill; F Marti Marti; M H Cullen; F Roila
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.

Authors:  Corrado Girmenia; Eleonora Russo; Ida Carmosino; Massimo Breccia; Francesco Dragoni; Roberto Latagliata; Sergio Mecarocci; Salvatore Giacomo Morano; Caterina Stefanizzi; Giuliana Alimena
Journal:  Ann Hematol       Date:  2007-01-16       Impact factor: 3.673

3.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

4.  Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.

Authors:  Shin Ahn; Yoon-Seon Lee; Yun-Hee Chun; In-Ho Kwon; Won Kim; Kyung Soo Lim; Tae Won Kim; Kyoo-Hyung Lee
Journal:  Support Care Cancer       Date:  2010-06-16       Impact factor: 3.603

5.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

6.  Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.

Authors:  Almarie Uys; Bernardo L Rapoport; Ronald Anderson
Journal:  Support Care Cancer       Date:  2004-06-09       Impact factor: 3.603

7.  Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.

Authors:  Helen Innes; Sheow Lei Lim; Allison Hall; Su Yin Chan; Neeraj Bhalla; Ernest Marshall
Journal:  Support Care Cancer       Date:  2007-09-25       Impact factor: 3.603

8.  Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.

Authors:  Nirmala Devi Baskaran; Gin Gin Gan; Kamarulzaman Adeeba
Journal:  Ann Hematol       Date:  2008-04-24       Impact factor: 3.673

9.  Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.

Authors:  A Uys; B L Rapoport; H Fickl; P W A Meyer; R Anderson
Journal:  Eur J Cancer Care (Engl)       Date:  2007-11       Impact factor: 2.520

10.  Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients.

Authors:  Elif Sahin Horasan; Gulden Ersoz; Anil Tombak; Naci Tiftik; Ali Kaya
Journal:  Med Sci Monit       Date:  2011-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.